Parkinson's Disease News and Research RSS Feed - Parkinson's Disease News and Research Twitter

Parkinson's disease is a brain disorder. It occurs when certain nerve cells (neurons) in a part of the brain called the substantia nigra die or become impaired. When approximately 80 percent of neurons are damaged, the symptoms of Parkinson's disease appear. Parkinson's disease affects 1 in 100 people over the age of 60, with the average age of onset being 60 years. The risk of developing Parkinson's disease increases with age. In the United States, it is estimated that 60,000 new cases of Parkinson's disease are diagnosed each year, with 1.5 million Americans currently living with the disease.
Study provides new route for treating patients with difficult-to-treat Parkinson's symptoms

Study provides new route for treating patients with difficult-to-treat Parkinson's symptoms

Parkinson's disease patients treated with low-frequency deep brain stimulation show significant improvements in swallowing dysfunction and freezing of gait over typical high-frequency treatment. [More]
TSRI scientists find drug candidates that can prevent degeneration of brain cells in Parkinson's

TSRI scientists find drug candidates that can prevent degeneration of brain cells in Parkinson's

In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have shown their drug candidates can target biological pathways involved in the destruction of brain cells in Parkinson's disease. [More]
International study identifies genetic factors that influence the size of brain structures

International study identifies genetic factors that influence the size of brain structures

An international study, which included researchers from NUI Galway, has identified significant genetic factors that influence the size of structures within the brain. It is hoped these new insights may help scientists better understand disorders such as schizophrenia, Alzheimer's disease and epilepsy. [More]
Scientists identify new molecular pathway that controls axonal degeneration following injury

Scientists identify new molecular pathway that controls axonal degeneration following injury

Axons connect neurons with each other to form the neural networks that underpin the vital functions of perception, motility, cognition, and memory. In many neurodegenerative disorders, from traumatic injury or toxic damage to diseases such as Alzheimer's or Parkinson's disease, axonal degeneration represents an essential pathological feature. [More]
Findings could lead to new therapeutic approach to Parkinson's disease

Findings could lead to new therapeutic approach to Parkinson's disease

E.. coli usually brings to mind food poisoning and beach closures, but researchers recently discovered a protein in E.. coli that inhibits the accumulation of potentially toxic amyloids--a hallmark of diseases such as Parkinson's. [More]
Researchers test pocket stimulator on patients with Parkinson's disease

Researchers test pocket stimulator on patients with Parkinson's disease

Parkinson's disease is a slowly degenerative neurological disease that is expressed as impaired motor control, tremors, stiffness and, in later stages, problems with balance. [More]
MU's Kattesh Katti named 2015 Hevesy Medal Award winner for contributing to nanomedicine

MU's Kattesh Katti named 2015 Hevesy Medal Award winner for contributing to nanomedicine

Gold nanoparticles have been proven useful in a number of medical applications. Scientists are developing nanoparticles to produce pharmaceuticals used in the imaging and diagnosis of diseases such as cancer, arthritis, Parkinson's disease and eye degeneration. [More]
Education can help people better understand individuals with facial paralysis

Education can help people better understand individuals with facial paralysis

A little bit of sensitivity training can help people form better first impressions of those with facial paralysis, reducing prejudices against people with a visible but often unrecognizable disability, new research from Oregon State University indicates. [More]
Joining a walking group helps boost overall health

Joining a walking group helps boost overall health

Joining a walking group is one of the best and easiest ways to boost overall health, with virtually no side effects, suggests an analysis of the available evidence, published online in the British Journal of Sports Medicine. [More]
Regular outdoor walking in groups boosts health, reduces life-threatening conditions

Regular outdoor walking in groups boosts health, reduces life-threatening conditions

Risk of stroke, coronary heart disease, depression and other life-threatening conditions can be reduced through regular outdoor walking in groups, according to research from the University of East Anglia. [More]
MRIGlobal awarded $54 million NIH contract to provide support for drug development

MRIGlobal awarded $54 million NIH contract to provide support for drug development

MRIGlobal today announced that it has been awarded a $54 million, 10-year program from the National Institute of Neurological Disorders and Stroke to provide support for the development and manufacturing of drug candidates for ultimate use in human clinical trials. [More]
Altos Therapeutics announces issuance of Mexican patent covering dopamine D2/D3 drug candidates

Altos Therapeutics announces issuance of Mexican patent covering dopamine D2/D3 drug candidates

Altos Therapeutics, LLC announced today that the Mexican Institute of Industrial Property has issued Patent Number 323020 titled, "D2 Antagonists, Methods of Synthesis and Methods of Use". The patent broadly and specifically covers the company's dopamine D2/D3 drug candidates, their pharmaceutical compositions, and their use to treat a number of important gastrointestinal conditions in humans, such as gastroparesis. [More]
Two leading biotechnology companies collaborate to gain further understanding of Parkinson’s disease

Two leading biotechnology companies collaborate to gain further understanding of Parkinson’s disease

This week 23andMe (a genetic testing company) and Genentech (medical research company of the Roche Group) agreed a collaboration to undertake whole genome sequencing for 3,000 patients with Parkinson’s disease. The genetic information will be collected by 23andMe and used by Genentech to identify new therapeutic targets for treating Parkinson’s disease. [More]
FDA approves RYTARY for Parkinson's disease treatment

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication. [More]
American Migraine Foundation plans to create Migraine Patient Registry and Biorepository

American Migraine Foundation plans to create Migraine Patient Registry and Biorepository

Migraine affects 36 million Americans, can have a major impact on patients' quality of life, and even on their relationships. The World Health Organization estimates that migraine is the third most prevalent medical disorder in the world, the 4th most disabling among women and the 7th most disabling overall. [More]
Research findings could lead to new drug design for neurological diseases

Research findings could lead to new drug design for neurological diseases

A new intermediate step and unexpected enzymatic activity in a metabolic pathway in the body, which could lead to new drug design for psychiatric and neurodegenerative diseases, has been discovered by researchers at Georgia State University. [More]
Study: Synthetic triglyceride oil may provide hope for people with Huntington's disease

Study: Synthetic triglyceride oil may provide hope for people with Huntington's disease

An early study suggests that a synthetic triglyceride oil called triheptanoin may provide hope for people with Huntington's disease. The study is published in the January 7, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
New study finds that exercise may improve lives of Parkinson's disease patients

New study finds that exercise may improve lives of Parkinson's disease patients

Exercise may help people with Parkinson's disease improve their balance, ability to move around and quality of life, even if it does not reduce their risk of falling, according to a new study published in the December 31, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, and its commercial and development partner Zambon S.p.A., an international pharmaceutical company, announced today that the NDA for safinamide has been re-submitted to the US FDA. [More]
FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor. [More]